ArticleJournal of orthopaedic case reports2026
Beyond Weight Loss: Effects of Semaglutide on Knee Pain, Physical Function, and Thigh Skeletal Muscle Volume in Obesity-Associated Knee Osteoarthritis.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Obesity is an important modifiable risk factor for knee osteoarthritis, contributing to pain, functional limitation, and systemic inflammation. Semaglutide may provide benefits beyond weight reduction, but its effects on clinical and functional outcomes in obesity-associated knee osteoarthritis remain insufficiently characterized. Against this background, this study sought to evaluate the effects of 6-month semaglutide treatment on weight, knee pain, physical function, thigh skeletal muscle volume, and inflammatory markers in patients with obesity-associated knee osteoarthritis. Materials and Methods: This prospective, observational, single-arm study included 75 patients with obesity-associated knee osteoarthritis who received semaglutide and were followed for 6 months. Changes in weight, body mass index (BMI), knee pain assessed by the Visual Analogue Scale (VAS), physical function assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), thigh skeletal muscle volume, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated. Results: At the 6-month follow-up, body weight decreased from 101.23 ± 15.45 to 91.47 ± 9.67 kg (mean change -9.76 kg), while BMI decreased from 34.49 ± 3.67 to 31.89 ± 5.78 kg/m2 (-2.60 kg/ m2; both P < 0.001). VAS pain scores decreased from 6.90 ± 2.10 to 4.89 ± 0.73 (-2.01; P < 0.001), and WOMAC scores improved from 59.67 ± 6.47 to 44.60 ± 6.12 (-15.07; P < 0.001). Thigh skeletal muscle volume increased from 10.6 ± 2.3 to 11.1 ± 1.8 L (+0.50 L; P < 0.001). CRP decreased from 6.14 ± 0.73 to 3.91 ± 2.08 mg/L, while ESR decreased from 27.51 ± 3.32 to 19.64 ± 4.37 mm/h. Conclusion: 6 months of semaglutide treatment was associated with substantial weight loss and significant improvements in knee pain and physical function, accompanied by reductions in systemic inflammatory markers. These findings suggest potential benefits of semaglutide beyond weight reduction in obesity-associated knee osteoarthritis. Larger controlled studies with longer follow-up are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.